S. Tjulandin

发表

Tamoxifen Never Ceases to Amaze: New Findings on Non-Estrogen Receptor Molecular Targets and Mediated Effects

T. Bogush, B. B. Polezhaev, I. Mamichev, 2018, Cancer investigation.

Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

Anton Belousov, Wolfgang Eiermann, M. Cheang, 2014, Clinical Cancer Research.

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

David Goldstein, Manuel Hidalgo, Thomas Ervin, 2013, The New England journal of medicine.

Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.

R. Holcombe, P. Jiang, S. Hingorani, 2015 .

Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.

A. Lluch, A. Makhson, M. Lichinitser, 2012, The oncologist.

Second-line treatment of metastatic gastric cancer: Current options and future directions.

S. Tjulandin, A. Tryakin, D. Kanagavel, 2015, World journal of gastroenterology.

Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models.

F. Daeyaert, J. Ludes-Meyers, S. Tjulandin, 2016, European journal of cancer.

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

T. De Pas, J. Pujol, M. Debois, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Colorectal cancer, screening: achievements и opportunities

S. Tjulandin, A. Tryakin, E. Polyanskaya, 2018, Colorectal Oncology.

Expression of Human Endogenous Retroviruses HERV-K/HTDV in Germ Cell Tumours: Possible Biological Role and Clinical Application

S. Tjulandin, A. Karseladze, T. Vinogradova, 2002 .

Preoperative chemotherapy in patients with resectable esophageal carcinoma: a single center Phase II study.

S. Tjulandin, A. Tryakin, M. Fedyanin, 2016, Japanese journal of clinical oncology.

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy

I. Bondarenko, S. Tjulandin, M. Šmakal, 2019, BMC Cancer.

Prognosis of stage II and III colon cancer treated with adjuvant 5-fl uorouracil or FOLFIRI in relation to microsatellite status : results of the PETACC-3 trial †

C. Bokemeyer, J. Tabernero, B. Melichar, 2014 .

Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.

Tae Won Kim, P. Ruff, M. Peeters, 2016, European journal of cancer.

A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer

V. Semiglazov, S. Tjulandin, S. Chan, 2010, Oncology Research and Treatment.

Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.

J. Ajani, C. Boni, E. Van Cutsem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of cancer drugs in patients with metastatic colorectal cancer in terms of mortality reduction

S. Tjulandin, A. Tryakin, M. Fedyanin, 2017 .

A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.

S. Tjulandin, I. Bazin, A. Garin, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

C. Bokemeyer, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.

R. Kreienberg, W. Jonat, N. Harbeck, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunofluorescent assay of ERCC1 and estimation of clinical significance of the protein expression in ovarian cancer tissue

T. Bogush, E. Bogush, S. Tjulandin, 2014, Doklady Biochemistry and Biophysics.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred.

D. Bishop, M. Stratton, K. Heimdal, 2010, Urologic oncology.

Somatic mutations of KIT in familial testicular germ cell tumours

Katherine M. Tucker, D. Easton, M. Stratton, 2004, British Journal of Cancer.

Real-world treatment patterns among patients with advanced gastric cancer in Russia: a chart review study

S. Tjulandin, P. Thompson-Leduc, W. Cheng, 2019, Journal of Drug Assessment.

Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.

M. Hidalgo, M. Reni, J. Tabernero, 2013 .

Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).

M. Hidalgo, M. Reni, E. Van Cutsem, 2013 .

Circulating tumor DNA as a marker of residual tumor in colon cancer

E. V. Moroz, S. Tjulandin, U. Boyarskikh, 2018, Colorectal Oncology.

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.

W. Gradishar, H. Iwata, S. Johnston, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.

S. Fosså, S. Culine, A. Horwich, 2008, European urology.

High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer

S. Tjulandin, N. I. Pospekhova, E. Ginter, 2007, Bulletin of Experimental Biology and Medicine.

Factors associated with disconcordance of KRAS, NRAS, BRAF, PIK3CA mutation status in the primary tumor and metastases in patients (pts) with colorectal cancer (CRC)

S. Tjulandin, S. Gordeev, A. Tryakin, 2016 .

2030 ORAL Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial

J. Baselga, W. Eiermann, A. Lluch, 2007 .

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.

A. Buzdar, B. Xu, D. Miles, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

6504 ORAL Safety and Efficacy of Epirubicin, Cisplatin, and Capecitabine (ECX) Plus Rilotumumab (R) as First-line Treatment for Unresectable Locally Advanced (LA) or Metastatic (M) Gastric or Esophagogastric Junction (EGJ) Adenocarcinoma

R. Donehower, S. Tjulandin, Yi-zhou Jiang, 2011 .

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

B. Monk, I. Vergote, S. Chan, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

E. Perez, R. Gelber, J. Baselga, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer

P. Povilaitite, S. Tjulandin, Y. Andreeva, 2018, Virchows Archiv.

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

D. Cunningham, B. Karaszewska, M. Tejani, 2015 .

Metastasectomy in patients with non-resectable metastatic colorectal cancer receiving chemotherapy and anti-EGFR antibodies: a prospective, non-randomized, multicenter, phase II study

S. Tjulandin, T. V. Ustinova, L. Bolotina, 2019, Colorectal Oncology.

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

Marc Peeters, Tae Won Kim, P. Ruff, 2014, The Lancet. Oncology.

Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis

S. Tjulandin, A. Tryakin, M. Fedyanin, 2019, Journal of Modern Oncology.

51A Docetaxel (D), cisplatin (C) 5-fluorouracil (F) compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325)

C. Boni, S. Tjulandin, E. Cutsem, 2003 .

96ODETERMINING THE PREVALENCE OF EGFR MUTATIONS IN ASIAN AND RUSSIAN PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC) OF ADENOCARCINOMA (ADC) AND NON-ADC HISTOLOGY: IGNITE STUDY

B. Han, N. Normanno, R. McCormack, 2015 .

35O_PRINVESTIGATING THE UTILITY OF CIRCULATING-FREE TUMOUR-DERIVED DNA (CTDNA) IN PLASMA FOR THE DETECTION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION STATUS IN EUROPEAN AND JAPANESE PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (ANSCLC): ASSESS STUDY

B. Han, N. Normanno, R. McCormack, 2015 .

Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.

S. Tjulandin, A. Garin, A. Tryakin, 2011, Urology.

O-0011FREQUENCY OF S492R MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR: ANALYSIS OF PLASMA DNA FROM METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH PANITUMUMAB OR CETUXIMAB MONOTHERAPY

Tae Won Kim, P. Ruff, M. Boedigheimer, 2014 .

Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors

S. Tjulandin, A. Garin, A. Tryakin, 2015, Journal of Cancer Research and Clinical Oncology.

Effect of the timing of orchiectomy on survival in patients with metastatic germ cell tumors of testis.

S. Tjulandin, A. Garin, A. Tryakin, 2014, Urologic oncology.

Treatment outcome of patients with brain metastases from malignant germ cell tumors

S. Fosså, S. Culine, C. Bokemeyer, 1999, Cancer.

Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.

S. Fosså, A. Dunant, S. Tjulandin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.

S. Tjulandin, A. Garin, A. Tryakin, 2013, Urologic oncology.

Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia.

A. Kudryavtseva, S. Tjulandin, M. Filipenko, 2019, Journal of Clinical Oncology.

First‐line checkpoint inhibitors in PD‐L1‐positive patients with advanced urothelial carcinoma

S. Tjulandin, I. Tsimafeyeu, 2018, BJU international.

Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER- HER2-positive breast cancers: Gene expression analysis.

J. Baselga, W. Eiermann, A. Lluch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)

J. Ajani, C. Boni, S. Tjulandin, 2005 .

Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial

S. Tjulandin, B. Gertz, P. Bias, 2011, Archives of drug information.

Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial

S. Tjulandin, B. Gertz, P. Bias, 2010, Archives of drug information.

Molecular features of ascitic ovarian cancer cells detected by immunofluorescence assay using flow cytometry

T. Bogush, E. Bogush, S. Tjulandin, 2016, Moscow University Chemistry Bulletin.

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

A. Markoe, R. Tishler, D. Shin, 2007, The New England journal of medicine.

Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise

Charles R. Thomas, S. Tjulandin, C. Degnin, 2020, Journal of Cancer Education.

Control of malignant ascites using HIPEC in 2 patients with ovarian cancer: A case-report

E. Bogush, S. Tjulandin, V. Kirsanov, 2020 .

A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer.

R. Holcombe, P. Jiang, S. Hingorani, 2013 .

The prediction of treatment outcomes in non-seminomatous extragonadal germ cell tumors (NSEGCT) by using different criteria of « poor » and « good » risk

S. Tjulandin, A. Garin, M. Mendoza, 1994 .

2707 Quantitative immunofluorescent detection of RRM1 protein in ovarian cancer tissue by flow cytometry

T. Bogush, S. Tjulandin, E. Dudko, 2015 .

Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens

V. Semiglazov, S. Tjulandin, L. Goldstein, 2005 .

Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer

A. Manikhas, P. Fumoleau, A. Lundberg, 2008 .

Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors.

R. Ozols, S. Tjulandin, V. Gorbunova, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

VAB-6 and cisplatin-cyclophosphamide combinations in the treatment of metastatic seminoma patients: the U.S.S.R. experience.

N. A. Vetrova, S. Tjulandin, A. Garin, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

W. Siegert, S. Fosså, S. Culine, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective study of prognostic role of plasma circulating tumor DNA (ctDNA) in patients (pts) with early-stage malignancies.

S. Tjulandin, M. Filipenko, A. Kechin, 2020, Journal of Clinical Oncology.

Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

Michael Hawkins, Neil Desai, W. Gradishar, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.

S. Fosså, S. Culine, A. Horwich, 2008, European urology.

The Y deletion gr/gr and susceptibility to testicular germ cell tumor.

M. Pike, M. Stratton, D. Forman, 2005, American journal of human genetics.

Genome-wide linkage screen for testicular germ cell tumour susceptibility loci.

M. Stratton, D. Forman, K. Heimdal, 2006, Human molecular genetics.

Overview of Female Germ Cell Tumours

S. Tjulandin, 2002 .

Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

R. Holcombe, N. Raghunand, H. Shepard, 2016, Clinical Cancer Research.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

J. Ajani, C. Boni, E. Van Cutsem, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer : A Report of the V 325 Study Group

J. Ajani, C. Boni, Y. Chao, 2006 .

Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

S. Culine, A. Horwich, P. Albers, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long term results of treatment in patients with extragonadal germ cell tumours.

S. Tjulandin, A. Garin, F. Delgado, 1993, European journal of cancer.

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

J. Baselga, B. Leyland-Jones, V. Semiglazov, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

E. Rutgers, M. Piccart, C. Denkert, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

D. Cunningham, B. Karaszewska, M. Tejani, 2017, The Lancet. Oncology.

Therapeutic approaches to gastroesophageal junction adenocarcinomas

A. Chang, M. Sosef, P. Swanson, 2014, Annals of the New York Academy of Sciences.

Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies

S. Tjulandin, A. Tryakin, M. Fedyanin, 2020, ESMO Open.

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

J. Mackey, A. Wardley, S. Tjulandin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen non-estrogen receptor mediated molecular targets

T. Bogush, E. Bogush, B. Polotsky, 2012, Oncology reviews.

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

J. Ajani, E. Van Cutsem, Y. Chao, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).

Tae Won Kim, P. Ruff, M. Boedigheimer, 2015 .

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

J. Baselga, M. Climent, W. Eiermann, 2014, The Lancet. Oncology.

EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study.

B. Han, N. Normanno, R. McCormack, 2017, Lung cancer.

Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study

P. Povilaitite, E. Imyanitov, S. Tjulandin, 2020, Scientific Reports.

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

A. Carrato, L. Lipton, C. Fuchs, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

B. Han, S. Novello, N. Normanno, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 1b Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer

R. Holcombe, N. Raghunand, H. Shepard, 2015 .

Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.

J. Ajani, C. Boni, E. Van Cutsem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors

D. Bishop, M. Stratton, K. Heimdal, 2008, Genes, chromosomes & cancer.

A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.

A. Macciocchi, F. Lordick, M. Aapro, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II

Liang Xiu, N. Bogdanova, J. Sparano, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.

J. Baselga, E. Kubista, Li-an Xu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

B. Wiens, C. Vogel, S. Tjulandin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design.

J. Bergh, C. Sotiriou, B. Gusterson, 2012, Breast.

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.

R. Tishler, D. Shin, L. Raez, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

HERV‐K(HML‐2) GAG/ENV antibodies as indicator for therapy effect in patients with germ cell tumors

S. Tjulandin, A. Karseladze, V. Gurtsevitch, 2004, International journal of cancer.

Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

T. Whelan, S. Aparicio, D. Huntsman, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

J. Baselga, W. Eiermann, A. Lluch, 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Maintenance therapy following first-line chemotherapy in metastatic colorectal cancer: toxicity and efficacy—single-institution experience

S. Tjulandin, S. Gordeev, A. Tryakin, 2014, Medical Oncology.

Paclitaxel and cisplatin as salvage treatment in patients with non-seminomatous germ cell tumour who failed to achieve a complete remission on induction chemotherapy.

S. Tjulandin, V. Breder, A. Garin, 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer

M. Desilvio, A. Manikhas, S. Tjulandin, 2010, Oncology.

Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis

J. Baselga, W. Eiermann, A. Lluch, 2007 .

A Phase II Multicenter Study of Two Different Dosages of Pemetrexed Given in Combination With Cyclophosphamide as First-Line Treatment in Patients With Locally Advanced or Metastatic Breast Cancer

K. Krejcy, A. Manikhas, I. Láng, 2012 .

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

G. Manikhas, S. Tjulandin, U. Keilholz, 2014, Investigational New Drugs.

Bridging the Gap in Global Advanced Radiation Oncology Training: Impact of a Web-Based Open-Access Interactive Three-Dimensional Contouring Atlas on Radiation Oncologist Practice in Russia

Charles R. Thomas, S. McClelland, S. Tjulandin, 2018, Journal of Cancer Education.

Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy

Tae Won Kim, P. Ruff, M. Boedigheimer, 2020, Cancer biology & therapy.

The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

M. Shah, Y. Bang, F. Lordick, 2018 .

Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.

W. Gradishar, M. Aapro, S. Tjulandin, 2011, Breast.

Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.

W. Gradishar, S. Johnston, S. Im, 2017 .

Olanzapine (OLN) versus aprepitant (APR) in patients receiving high-emetogenic chemotherapy: Final results of randomized phase II trial.

S. Tjulandin, A. Tryakin, M. Fedyanin, 2019, Journal of Clinical Oncology.

Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens.

V. Semiglazov, E. Bayever, S. Tjulandin, 2014, Clinical breast cancer.

Started dose of regorafenib and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): A systematic review and meta-analysis.

S. Tjulandin, A. Tryakin, M. Fedyanin, 2020 .

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

C. Bokemeyer, E. Van Cutsem, J. Tabernero, 2015 .

Targeted therapy in the treatment of solid tumors: Practice contradicts theory

N. V. Zhukov, S. Tjulandin, S. A. Tjulandin, 2008, Biochemistry (Moscow).

A Phase II Nonrandomized Study of Oxaliplatin/Doxorubicin Combination Therapy in the Treatment of Recurrent Ovarian Cancer

S. Tjulandin, A. Tryakin, M. Fedyanin, 2013 .

W. Gradishar, H. Iwata, S. Johnston, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Circulating tumor cells and circulating tumor DNA in colon cancer

S. Tjulandin, M. Fedyanin, E. Polyanskaya, 2016, memo - Magazine of European Medical Oncology.

Patterns of Care and Barriers to Utilization of Definitive Concurrent Chemoradiation Therapy for Stage III Non-Small Cell Lung Cancer in Russia

Charles R. Thomas, S. Tjulandin, C. Degnin, 2021, Journal of Cancer Education.

Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: Results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC.

S. Tjulandin, D. Stroyakovskiy, G. Adamchuk, 2015 .

Double siRNA-targeting of cIAP2 and LIVIN results in synergetic sensitization of HCT-116 cells to oxaliplatin treatment

S. Tjulandin, S. Poyarkov, A. Karpukhin, 2013, OncoTargets and therapy.

Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.

T. Powles, T. Choueiri, B. Melichar, 2023, The Lancet. Oncology.

Updated Efficacy, Biomarker, and Exposure-Response Data from a Phase 2 Study of Rilotumumab (R) Plus Epirubicin, Cisplatin, and Capecitabine (ECX) in Gastric (G) or Esophagogastric Junction (EGJ) Cancer

R. Donehower, S. Tjulandin, Yi-zhou Jiang, 2012 .

Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: Results from a comparative phase III trial

M. Lichinitser, J. Body, S. Tjulandin, 2005 .

485 Influence of disease free interval on the efficacy of capecitabine-bevacizumab for HER2-negative metastatic breast cancer (MBC) in the RIBBON-1 trial

S. Tjulandin, A. Brufsky, O. Ponomarova, 2010 .

487 Efficacy of first-line capecitabine plus bevacizumab in patients with ER/PgR-positive metastatic breast cancer (MBC) and those previously treated with hormone therapy

V. Semiglazov, V. Diéras, S. Tjulandin, 2010 .

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.

M. Lichinitser, J. Body, S. Tjulandin, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients.

S. Tjulandin, M. Nechaeva, M. Kopp, 2014 .

Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise

Charles R. Thomas, S. Tjulandin, C. Degnin, 2019, Journal of Cancer Education.

Bridging the Gap in Global Advanced Radiation Oncology Training: Impact of a Web-Based Open-Access Interactive Three-Dimensional Contouring Atlas on Radiation Oncologist Practice in Russia

Charles R. Thomas, S. McClelland, S. Tjulandin, 2018, Journal of Cancer Education.

Testicular Cancer in Russia

V. Dvoirin, S. Tjulandin, A. Garin, 1994 .

Predictive Biomarkers and Personalized Medicine Research-Based PAM 50 Subtype Predictor Identi fi es Higher Responses and Improved Survival Outcomes in HER 2-Positive Breast Cancer in the NOAH Study

M. Cheang, W. Eiermann, A. Prat, 2014 .

Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies

F. Daeyaert, D. Harrison, S. Tjulandin, 2017, Investigational New Drugs.

A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer

S. Tjulandin, V. Moiseyenko, I. Utyashev, 2023, Investigational new drugs.

Abstract 4586: FGFR2 amplification in serous ovarian cancer

S. Tjulandin, I. Demidova, I. Tsimafeyeu, 2016 .

Molecular Modeling, de novo Design and Synthesis of a Novel, Extracellular Binding Fibroblast Growth Factor Receptor 2 Inhibitor Alofanib (RPT835).

F. Daeyaert, J. Ludes-Meyers, S. Tjulandin, 2016, Medicinal chemistry.

1449MO Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study

R. Motzer, B. Melichar, S. Tjulandin, 2022, Annals of Oncology.

Abstract 1241: Profile of BRCA1/BRCA2 mutations in Russian ovarian cancer population detected by NGS and MLPA analysis: Interim results of OVATAR study

E. Imyanitov, S. Tjulandin, I. Demidova, 2018, Epidemiology.

Flow cytometric analysis of the ERCC1, marker of DNA damage repair, in the tumor specimens embedded into paraffin blocks

T. Bogush, E. Bogush, B. Polotsky, 2017, Doklady Biochemistry and Biophysics.

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Y. Wang, A. Schneeweiss, Ming Yan, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Quantitative immunofluorescence estimation of Pgp expression in human solid tumors by flow cytometry

T. Bogush, B. Polotsky, S. Tjulandin, 2012, Moscow University Chemistry Bulletin.

Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparative bone turnover marker and safety data

J. Body, S. Tjulandin, B. Bergström, 2006 .

Intravenous and oral ibandronate have better safety and tolerability profiles than zoledronic acid: evidence from comparative phase III trials

J. Body, S. Tjulandin, B. Bergström, 2006 .

Overall Survival of Patients With ALK-Positive Metastatic Non–Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study

E. Imyanitov, S. Tjulandin, F. Moiseenko, 2019, Journal of global oncology.

Phase 1 study of picoplatin (pico) in combination with 5-fluorouracil (FU) and leucovorin (LV) as initial therapy in subjects with metastatic colorectal cancer (CRC)

S. Tjulandin, O. Gladkov, D. Karlin, 2007 .

39P Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: A phase Ib study in patients with advanced gastric cancer (RPT835GC1B)

S. Tjulandin, I. Tsimafeyeu, M. Byakhov, 2021 .

Estrogen Receptors alpha and beta in Ovarian Cancer: Expression Level and Prognosis

T. Bogush, E. Bogush, S. Tjulandin, 2018, Doklady Biochemistry and Biophysics.

Non-interventional study OVATAR final report: Diagnostic and treatment approaches in Russian ovarian cancer population—BRCAm group analysis.

S. Tjulandin, V. Gorbunova, A. Lisyanskaya, 2019, Journal of Clinical Oncology.

Role of FGFR2 amplification in prognosis of patients with ovarian cancer.

S. Tjulandin, A. Tyulyandina, M. Gikalo, 2018, Annals of Oncology.

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

B. Han, S. Novello, N. Normanno, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tae Won Kim, P. Ruff, M. Peeters, 2014, The Lancet. Oncology.

ESMO takes a stand on supportive and palliative care.

M. Maltoni, M. Tonato, S. Tjulandin, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer: primary efficacy analysis of the NOAH trial.

J. Baselga, W. Eiermann, A. Lluch, 2009 .

Pegylated liposomal doxorubicin (PLD) plus docetaxel significantly improves time to progression (TTP) compared with docetaxel (D) monotherapy in patients with advanced breast cancer (ABC) treated with adjuvant anthracycline: results from a randomized phase 3 study.

N. Bogdanova, J. Sparano, V. Semiglazov, 2009 .